The Independent Data Monitoring Committee halted the trial, which had recruited patients who tested positive for PD-L1 in more than 50% of tumour cells, after a decrease in relative risk of death by 32.4% was seen with cemiplimab compared to chemotherapy.

SPS commentary:

Cemiplimab monotherapy is currently licensed for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.